Document is current
Any future updates will be listed below
-
Authors
Zhang, Fucai
Xie, Jingyi
Li, Yong
Feng, Wenlu
Su, Jianfen
Mao, Nan
-
Funding
Funding for this research was provided by:
Guangdong Basic and Applied Basic Research Fund Enterprise Joint Fund (2023A1515220024)
Medical Research Foundation of Guangdong Province (2024070)
Guangdong Hospital Pharmaceutical Research Fund project funding (2024A31)
Research Funds from Guangzhou Panyu Central Hospital (PY-2023-007, PY-2023-010, and PY-2023-026)
- License Information
-
More Information
Article History
Received: 7 January 2026
Accepted: 18 August 2026
First Online: 21 August 2026
Declarations
Ethics approval and informed consent: The clinical protocol received approval from the Ethics Committee of Drug Clinical Trials, Panyu District Central Hospital, Guangzhou, China(PYZXYYEC2022-004 and PYZXYYEC2022-003). This study was conducted in compliance with the Declaration of Helsinki (1989), Good Clinical Practice guidelines, and relevant local laws and regulations. Written informed consent was obtained from all participants prior to participation. Clinical trial registration number: CTR20221098 and CTR20220627.
Consent for publication: Informed consent was obtained from all subjects in a clear and thorough manner, and their personal information was strictly protected from disclosure or public release.
Competing interests: The authors declare no competing interests.
